- Home
- GDL vs COYA Comparison
GDL vs COYA Comparison
Compare GDL & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- COYA
- Stock Information
- Founded
- GDL 2006
- COYA 2020
- Country
- GDL United States
- COYA United States
- Employees
- GDL N/A
- COYA N/A
- Industry
- GDL Investment Managers
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- GDL Finance
- COYA Health Care
- Exchange
- GDL Nasdaq
- COYA Nasdaq
- Market Cap
- GDL 91.7M
- COYA 99.8M
- IPO Year
- GDL N/A
- COYA 2022
- Fundamental
- Price
- GDL $8.38
- COYA $5.53
- Analyst Decision
- GDL
- COYA Strong Buy
- Analyst Count
- GDL 0
- COYA 4
- Target Price
- GDL N/A
- COYA $17.00
- AVG Volume (30 Days)
- GDL 11.2K
- COYA 42.5K
- Earning Date
- GDL 01-01-0001
- COYA 05-13-2025
- Dividend Yield
- GDL 6.02%
- COYA N/A
- EPS Growth
- GDL N/A
- COYA N/A
- EPS
- GDL N/A
- COYA N/A
- Revenue
- GDL N/A
- COYA $3,685,107.00
- Revenue This Year
- GDL N/A
- COYA $94.45
- Revenue Next Year
- GDL N/A
- COYA N/A
- P/E Ratio
- GDL N/A
- COYA N/A
- Revenue Growth
- GDL N/A
- COYA N/A
- 52 Week Low
- GDL $7.65
- COYA $4.65
- 52 Week High
- GDL $8.13
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- GDL 60.07
- COYA 41.95
- Support Level
- GDL $8.34
- COYA $5.27
- Resistance Level
- GDL $8.44
- COYA $5.99
- Average True Range (ATR)
- GDL 0.06
- COYA 0.30
- MACD
- GDL 0.01
- COYA -0.05
- Stochastic Oscillator
- GDL 68.00
- COYA 18.14
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.